Join Gerald Platteau, Senior Application Development Engineer, for a webinar on Amsphere A3, our alkali stable Protein A resin, that has shown to be an effective platform capture step for a wide range of antibody fragment variants. New biological modalities are rapidly emerging as candidate therapeutics for challenging disease targets.
Stepping away from the classical antibody constructs comes with challenges, as modifications are necessary to develop an effective and robust manufacturing process on an accelerated timeline.
Amsphere A3, an alkali-stable Protein A resin, has shown to be an effective platform capture step for a wide range of antibody fragment variants, which enables significantly more convenience in developing downstream processes for these types of biotherapeutics.
.png?width=300&height=71&name=JSR%20LS%20White%20Horizontal%20Logo%202019OCT62019%20(1).png)
.png?width=150&height=36&name=JSR%20LS%20White%20Horizontal%20Logo%202019OCT62019%20(1).png "JSR LS White Horizontal Logo 2019OCT62019 (1)"){kind=small}